Wexford Capital’s Ascendis Pharma A/S ASND Stock Holding History

Wexford Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,000	Closed	-$779K	–	248
2025 Q1	$779K	Buy	+5,000	New	+$714K	0.2%	91
2020 Q4	–	Sell	-5,000	Closed	-$772K	–	308
2020 Q3	$772K	Buy	+5,000	New	+$719K	0.21%	79
2020 Q2	–	Sell	-4,195	Closed	-$472K	–	189
2020 Q1	$472K	Sell	4,195 -805	-16%	-$105K	0.17%	66
2019 Q4	$696K	Sell	5,000 -5,000	-50%	-$555K	0.11%	94
2019 Q3	$963K	Hold	10,000	–	–	0.13%	79
2019 Q2	$1.15M	Hold	10,000	–	–	0.13%	80
2019 Q1	$1.18M	Hold	10,000	–	–	0.1%	64
2018 Q4	$627K	Hold	10,000	–	–	0.05%	62
2018 Q3	$709K	Hold	10,000	–	–	0.05%	111
2018 Q2	$665K	Buy	+10,000	New	+$658K	0.04%	99

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wexford Capital's ASND Position: Q2 2025 in Review

Wexford Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 5,000 shares — an estimated $779K sold.

Wexford Capital first reported a position in ASND in Q2 2018 and held it in 10 quarters. The position peaked at $1.18M in Q1 2019. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

Wexford Capital reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
Wexford Capital sold 5,000 Ascendis Pharma A/S shares in Q2 2025, an estimated $779K.
Wexford Capital first reported a position in Ascendis Pharma A/S in Q2 2018 and held it in 10 quarters.
Wexford Capital's Ascendis Pharma A/S position peaked at $1.18M in Q1 2019.
247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.